PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia^†

References

• Howlander N, Noone AM, Krapcho M, et al. April 2016 December. SEER Cancer Statistics Review, 1975–2013. Accessed 2016 December. Available from: https://seer.cancer.gov/csr/1975_2013/
   Google Scholar
• Sasaki K, Jabbour E, O'Brien S, et al. Outcome of patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) by age group over 35 years: a single institution experience ASH Annual Meeting Abstracts; 2016. p. 3975.
   Google Scholar
• Hunger SP, Loh ML, Whitlock JA, et al. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957–963.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9:e85554.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Thomas DA, O’Brien SM, et al. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014;120:3660–3668.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–1654.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218.
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose l-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7161–7167.
   PubMed Web of Science ®Google Scholar
• DeAngelo D, Stevenson K, Neuberg D, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial. ASH Annual Meeting Abstracts; 2015.
   Google Scholar
• Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31:58–64.
   PubMed Web of Science ®Google Scholar
• 2016 Acute Lymphoblastic Leukemia Version 2.2016. National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
   Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473.
   Google Scholar
• Kadia TM, Kantarjian HM, Thomas DA, et al. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015;90:120–124.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007;109:4164–4167.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmaco-dynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32:905–911.
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Gimotty PA, Gelfand J, et al. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol. 2016;91:1107–1112.
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Bunpo P, Cundiff JK, et al. The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab. 2013;305:E1124–11E1133.
   PubMed Web of Science ®Google Scholar
• Bunpo P, Dudley A, Cundiff JK, et al. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem. 2009;284:32742–32749.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23:295–299.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Sulz M, Stadlmann S, et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006;74:28–32.
   PubMed Web of Science ®Google Scholar
• Duarte X, Esteves S, Neto AM, et al. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study. Br J Haemat. 2016;174:280–291.
   PubMed Web of Science ®Google Scholar
• Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2017; DOI:1078155217701291
   PubMedGoogle Scholar
• Weiss J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Deutsches Arzteblatt Int. 2014;111:447–452.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Baumann A, Beck J, et al. PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003. Blood. 2010;116:494.
   Web of Science ®Google Scholar
• Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009;114:5146–5151.
   PubMed Web of Science ®Google Scholar
• Athale UH, Siciliano SA, Crowther M, et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129:803–810.
   PubMed Web of Science ®Google Scholar
• Roesmann A, Afify M, Panse J, et al. L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy. 2013;59:167–175.
   PubMed Web of Science ®Google Scholar
• Abd-Allah AR, Al-Majed AA, Al-Yahya AA, et al. L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol. 2005;79:406–413.
   PubMed Web of Science ®Google Scholar
• Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma. 2014;55:1670–1674.
   PubMed Web of Science ®Google Scholar
• Alshiekh-Nasany R, Douer D. L-Carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135:208–210.
   PubMed Web of Science ®Google Scholar
• Lu G, Karur V, Herrington JD, et al. Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine. Proc (Bayl Univ Med Cent). 2016;29:46–47.
   PubMedGoogle Scholar
• Law JY, Dao BD, Le P, et al. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. J Clin Oncol. 2015;33:e18051–e18051.
   Web of Science ®Google Scholar